NCTN Restricted Capitation - GY9

Over e Rall： 公共资助的癌症临床试验继续建立新的护理标准并改善 癌症患者的结局。ECOG-ACRIN(EA)建立了一个基于 生物和影像研究与抗癌新药临床试验的结合 进行尖端临床研究和促进科学发现的疗法。我们有 将成像、癌症生物学和治疗方面的专业知识整合到我们的科学组织中， 与达纳·法伯癌症中心的生物统计和数据管理中心密切合作 研究所和布朗大学提出一项研究计划，认识到 生物标记物为广大癌症患者带来精确的靶向临床试验。这个 EA生物信息库、图像数据库、免疫实验室和相关的翻译 科学中心将汇集与癌症生物学有关的相关科学研究 在数据丰富的环境中衡量治疗效果的临床标志。EA拥抱目标和精神 进行科学驱动的临床试验，以改善成年癌症患者的生活。 EA临床试验通过高效的运营基础设施实施，该基础设施能够 从大型癌症中心到社区，美国各地都能获得尖端治疗 实践和保证对不同患病率的癌症进行复杂的试验。我们的科学 是由我们的成员推动的，其中包括NCI资助的癌症中心，专门的 卓越研究计划(孢子)，ETCTN(实验治疗临床) 试验网络)、定量成像网络(QIN)、NCTN牵头学术参与 站点(LAPS)和国家社区肿瘤学研究计划(NCORP)。AS NCTN和CTEP领导的癌症研究的所有方面的坚定参与者，EA 在整个系统内协作，以促进和推进所有团体的集体努力。 我们提供所需的指导和机会，以滋养下一代 调查人员。EA的定位是为NCTN做出独特的贡献，努力翻译 NCI支持的科学为改善癌症患者的预后创造了条件。这一模式与 发展大数据分析方面的创新，将产生高质量的试验，这些试验具有以下潜力 实践改变，适用于学术和社区环境，并提供 成像和其他生物标记物，以确定受益最大的患者。

Ov e rall: Publicly-funded cancer clinical trials continue to establish new standards of care and improve outcomes for cancer patients. ECOG-ACRIN (EA) has instituted an organizational matrix based on the integration of biological and imaging studies with clinical trials of novel anti-cancer therapies to conduct cutting-edge clinical research and promote scientific discovery. We have incorporated expertise in imaging, cancer biology and therapy within our scientific organization, working closely with the biostatistics and data management centers at the Dana Farber Cancer Institute and Brown University, to propose a research plan that recognizes the importance of biomarkers to bring precisely targeted clinical trials to broad populations of cancer patients. The EA biorepositories, image databases, immunological laboratories, and associated translational science centers will bring together the correlative science studies that relate cancer biology to clinical markers of treatment effect in a data-rich environment. EA embraces the goals and spirit of the NCTN to conduct science-driven clinical trials to improve the lives of adults with cancer. EA clinical trials are implemented through an efficient operational infrastructure that enables access to cutting-edge treatments across the US from large cancer centers to community practices and assures accrual to complex trials in cancers of varying prevalence. Our science is driven by our membership, which includes the NCI-funded Cancer Centers, the Specialized Programs of Research Excellence (SPOREs), the ETCTN (Experimental Therapeutics Clinical Trials Network), the Quantitative Imaging Network (QIN), the NCTN Lead Academic Participating Sites (LAPS), and the National Community Oncology Research Programs (NCORP). As committed participants in the NCTN and in all aspects of CTEP-led cancer research, EA collaborates across the system to promote and advance the collective efforts of all of the groups. We make available the mentorship and opportunity needed to nourish the next generation of investigators. EA is positioned to make unique contributions to the NCTN, working to translate NCI-supported science into improved outcomes for cancer patients. This model, together with developing innovation in large data analysis, will yield high quality trials that have the potential to be practice-changing, applicable to both academic and community environments, and providing imaging and other biomarkers to identify patients who benefit most.